Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21980930 | 0.88 | KEAP1 (0.38) | JAK2ALDH1A1LMNAHTR2CKMT2A | |
| SCHEMBL12594056 | 0.84 | JAK2 (0.43) | JAK2ALDH1A1LMNAHTR2CKMT2A | |
| SCHEMBL17350075 | 0.82 | JAK2 (0.42) | JAK2ALDH1A1LMNAHTR2CKMT2A | |
| SCHEMBL13268408 | 0.76 | LMNA (0.41) | ALDH1A1LMNAHTR2CKMT2AMEN1 | |
| SCHEMBL12595048 | 0.75 | ALDH1A1 (0.43) | JAK2ALDH1A1HTR2CKMT2AMEN1 | |
| SCHEMBL1980785 | 0.74 | ALDH1A1 (0.45) | ALDH1A1LMNAHTR2CKMT2AMEN1 | |
| SCHEMBL21980924 | 0.71 | SUV39H2 (0.42) | JAK2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL13832421 | 0.71 | SUV39H2 (0.42) | JAK2ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL12593952 | 0.71 | KEAP1 (0.45) | JAK2ALDH1A1LMNAHTR2CKMT2A | |
| SCHEMBL13721340 | 0.70 | ALDH1A1 (0.40) | ALDH1A1LMNAHTR2CKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | JAK2 1654/4885ALDH1A1 848/4885LMNA 2187/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | JAK2 1654/4885ALDH1A1 848/4885LMNA 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.